Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - Kinnate Biopharma Inc. | brhc10024565_ex32-2.htm |
EX-31.2 - EXHIBIT 31.2 - Kinnate Biopharma Inc. | brhc10024565_ex31-2.htm |
EX-31.1 - EXHIBIT 31.1 - Kinnate Biopharma Inc. | brhc10024565_ex31-1.htm |
10-Q - 10-Q - Kinnate Biopharma Inc. | brhc10024565_10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Kinnate Biopharma Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”),
I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: May 17, 2021
|
By:
|
/s/ Nima Farzan
|
Nima Farzan
|
||
President and Chief Executive Officer
(Principal Executive Officer)
|